MedPath

Omega-3 Fatty Acid Supplementation to Enhance Performance

Not Applicable
Completed
Conditions
Body Composition
Strength
Muscle Soreness
Interventions
Dietary Supplement: Omega-3 fatty acid
Dietary Supplement: Placebo
Registration Number
NCT05924139
Lead Sponsor
Baylor University
Brief Summary

The goal of this intervention study is to determine if omega-3 fatty acid supplementation as compared to placebo improves performance in track and field athletes. The main questions it aims to answer are:

1. Can performance be improved

2. Can strength be enhanced

3. Will positive body composition changes occur (lean vs fat mass)

4. Will feelings of muscle soreness be diminished Participants will take either omega-3 fatty acid supplements or placebo and continue with their sport specific training regimen.

Researchers will compare the supplement group to placebo group to determine if there are any significant differences.

Detailed Description

This is a randomized, placebo-controlled trial to determine the efficacy of fish oil-derived omega-3 fatty acid supplementation. Up to sixty participants will be randomized to receive one of two conditions: 4.0 grams of FO n-3/day or placebo (coconut oil) for the 10-week protocol study period. Nordic Naturals (Ultimate Omega) will be used as the intervention at a dose of 6 capsules/day (3840 mg total FO/1950 mg EPA/1350 mg DHA). Although protocols have varied among studies with regards to dosage, the proposed regimen was selected based on studies on strength in older adults and college-aged athletes utilizing a range of 2-5g FO n-3 per day. Blinded randomization will be accomplished with a research associate providing every first (of two) participants the placebo, while the second will receive the supplemented condition until recruitment is complete. Participants will be provided their supplement in 2-week increments and instructed to consume with/near their evening meal. Used bottles will be returned after two weeks and participants will receive the next 2-week supply of supplement and the leftover pill count will determine compliance rate.

The target population is apparently healthy college athletes (male and female of all ethnicities) between the ages of 18-25 years at Baylor University. Participants must be able to read and understand English and sign their own consent form. Up to 60 subjects will be recruited via direct contact or team briefings with permission of the coaches.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
33
Inclusion Criteria

Apparently healthy college athletes (male and female of all ethnicities) between the ages of 18-25 years.

Exclusion Criteria

-Participants will be excluded if they are unable to physically train due to injury/illness or are pregnant, or have a known heart condition or pacemaker.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Omega-3 fatty acidOmega-3 fatty acidNordic Naturals (Ultimate Omega) will be used as the intervention at a dose of 4 grams/day (3840 mg total fish oil with 1950 mg EPA and 1350 mg DHA
Coconut oilPlacebodose of 4 grams/day
Primary Outcome Measures
NameTimeMethod
Strengthchange from baseline at 8 weeks

lower body strength will be evaluated via a counter movement jump

Powerchange from baseline at 8 weeks

handgrip strength will be used as a proxy for upper body strength via a dynamometer

Secondary Outcome Measures
NameTimeMethod
Body compositionchange from baseline at 8 weeks

bioelectrical impedance analysis (BIA), a double-indirect body composition technique based on a 3-component model (fat mass, fat-free mass, and total body water), will be performed.

Muscle sorenesschange from baseline, every 2 weeks and at 8 weeks

Subjects will be asked to rate their muscle soreness on a 10-point Likert scale

Omega-3 indexchange from baseline at 8 weeks

The Omega-3 Index provides information on the participants baseline level of EPA/DHA level in the blood

Trial Locations

Locations (1)

Baylor University

🇺🇸

Waco, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath